Levofloxacino Aurovitas

Levofloxacin, the active ingredient in Levofloxacino Aurovitas, is a fluoroquinolone antibiotic presented as an intravenous injection for systemic use. It is employed to treat a range of serious bacterial infections, including community‑acquired and hospital‑acquired pneumonia, complicated urinary tract infections, intra‑abdominal infections, and skin and soft‑tissue infections in adult patients. These infections often require hospitalisation and prompt intravenous therapy.

GNH USA supplies Levofloxacino Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide across multiple regions, including Europe and Asia.

Levofloxacin is a fluoroquinolone antibiotic indicated for several serious bacterial infections. - Community‑acquired pneumonia: eradicates the causative pathogens and improves respiratory function. - Hospital‑acquired pneumonia: provides broad‑spectrum coverage for resistant organisms in hospitalized patients. - Complicated urinary tract infections: eliminates uropathogens in upper urinary tract involvement. - Complicated intra‑abdominal infections: treats polymicrobial infections following abdominal surgery or perforation. - Skin and soft‑tissue infections: resolves bacterial cellulitis and related soft‑tissue conditions.

Levofloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur without warning. - QT interval prolongation: can lead to cardiac arrhythmias. - Clostridioides difficile infection: severe colitis following disruption of gut flora.

When using Levofloxacino Aurovitas, clinicians should observe several safety considerations. - Renal function monitoring: adjust dosing in patients with impaired clearance. - Tendon disorder caution: avoid in individuals with a history of tendon inflammation or recent corticosteroid use. - QT prolongation risk: assess baseline ECG and avoid concomitant QT‑prolonging drugs. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Elderly patients: monitor for increased susceptibility to adverse effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levofloxacin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Antacids or supplements containing magnesium, aluminum, calcium, or iron: reduce levofloxacin absorption. - Warfarin: may increase INR and bleeding risk. - Cyclosporine: elevated cyclosporine concentrations can occur.

Moderate Interactions (Monitor Closely): - NSAIDs: heightened risk of central nervous system stimulation. - Systemic corticosteroids: increased chance of tendon rupture. - Other QT‑prolonging agents: additive effect on cardiac repolarization. - Diabetic agents (e.g., insulin, sulfonylureas): potential for hypoglycemia.